Overview

The Effects of AZD2171 in Patients With Non-Small Cell Lung Cancer or Head & Neck Cancer

Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
This study is to examine the effects on tumors of AZD2171, in the treatment of NSCLC or HNC. The safety and tolerability of AZD2171 will also be studied.
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca
Treatments:
Cediranib